Eupraxia Pharmaceuticals (EPRX) Current Leases (2022 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Current Leases of $203510.0 for Q1 2026, up 285.63% year-over-year from $52774.0 in Q1 2025, and up 159.41% quarter-over-quarter from $78452.0 in Q4 2025.
Powered by 
Analysis
Eupraxia Pharmaceuticals (EPRX) Current Leases (2022 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Current Leases for 5 consecutive years, with $203510.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases rose 285.63% year-over-year to $203510.0; the TTM figure through Mar 2026 stood at $203510.0 (up 285.63% YoY), while the FY2025 annual figure was $78452.0, up 9.17% from the prior year.
- Current Leases grew to $203510.0 in Q1 2026 per EPRX's latest filing, from $78452.0 in the prior quarter.
- Across five years, Current Leases topped out at $203510.0 in Q1 2026 and bottomed at $35065.0 in Q2 2025.
- Historically, Current Leases has averaged $77689.4 across 5 years, with a median of $62587.5 in 2023.
- Annual changes were most pronounced in 2023 — Current Leases increased 5.78% — and 2026, when it surged 285.63%.
- Eupraxia Pharmaceuticals' Current Leases stood at $50403.0 in 2022, then rose by 5.78% to $53316.0 in 2023, then soared by 34.78% to $71859.0 in 2024, then increased by 9.17% to $78452.0 in 2025, then jumped by 159.41% to $203510.0 in 2026.
- Business Quant data shows EPRX's Current Leases at $203510.0 in Q1 2026, $78452.0 in Q4 2025, and $76136.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Eupraxia Pharmaceuticals | 317.25 Mn | 317.25 Mn | - | 159,877.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 159,877.00 |
| Mar 31, 2026 | 203,510.00 |
| Dec 31, 2025 | 78,452.00 |
| Sep 30, 2025 | 76,136.00 |
| Jun 30, 2025 | 35,065.00 |
| Mar 31, 2025 | 52,774.00 |
| Dec 31, 2024 | 71,859.00 |
| Sep 30, 2024 | 14,297.00 |
| Jun 30, 2024 | 34,952.00 |
| Dec 31, 2023 | 53,316.00 |
| Dec 31, 2022 | 50,403.00 |